

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1445/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Use as many sheets as necessary.

Share

101

DUPLICATE

U.S. PATENT DOCUMENTS

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|----------------|--|----------------------|---|---|
| Examiner initials* | Cite No.* | Document Number | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | MM-DD-YYYY | | |
| AA* | US-5,591,85 | 01-07-1997 | Alexander | | |
| AB* | US-5,656,745 | 08-12-1997 | Bischofberger et al. | | |
| AC* | US-5,717,095 | 02-10-1998 | Armilli et al. | | |
| AD* | US-5,756,486 | 05-26-1998 | Alexander et al. | | |
| AE* | US-5,886,179 | 03-23-1999 | Armilli et al. | | |
| AF* | US-6,225,460 | 05-01-2001 | Bischofberger et al. | | |
| AG* | US-7,390,791 | 06-24-2008 | Becker et al. | | |
| AH* | US-20020119443 | 08-28-2002 | Becker et al. | | |

FOREIGN PATENT DOCUMENTS

Examiner Signature _____ Date Considered _____

***EXAMINER:** Initial if a difference is considered, whether or not citation is in conformance with MPEP 609. Draw through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those applications* which are marked with an asterisk (*) next to the Cite No. and/or supplier (under 37 CFR 1.96(e)(2)(ii)) indicate that the application was filed after June 30, 2003 or is available in the USPTO's electronic database. Those applications* which are marked with an asterisk (*) next to the Cite No. are not supplied because they were previously cited by or admitted to the Office. * A copy of the cited application is being supplied to the Office. * Applications for design patents are not supplied. * Applications for utility models are not supplied. * Applications for trademarks are not supplied. * Applications for plant patents are not supplied. * CITE NO.: Enter the serial number of the cited application. * If a copy of the cited application is being supplied to the Office, enter the serial number of the cited application. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. * Applicant is to place a checkmark if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

2

duplicate

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 10/785,497 |
| Filing Date | February 24, 2004 |
| First Named Inventor | Mark W. Becker et al. |
| Art Unit | 1657 |
| Examiner Name | P.C. Martin |
| Attorney Docket Number | 249.P2 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|-------------------|--|--|----------------|
| CA | Beach et al. (1998) "Chemotherapeutic agents for human immunodeficiency virus infection: Mechanism of action, pharmacokinetics, metabolism, and adverse interactions." <i>Clinical Therapeutics</i> 20(1):2-25 | | |
| CB | CAMP, N.P. et al. (1995) "Synthesis of Peptide Analogues Containing Phosphonamide Methyl Ester Functionality: HIV-1 Proteinase Inhibitors Possessing Unique Cell Uptake Properties." | | |
| CC | Cihlar et al. (2006) "Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonate-mediated solvent anchoring." <i>Journal of Molecular Biology</i> 363(3):635-647 | | |
| CD | Eddershaw et al. (2000) "ADME/PK as part of a rational approach to drug discovery" <i>Drug Discovery Today</i> 5(9):409-414 | | |
| CE | FRANCHETTI, P., et al. (1998) "Potent and Selective Inhibitors of Human Immunodeficiency Virus Protease Structurally Related to -94,746." <i>Antiviral Chemistry & Chemotherapy</i> 9(4):303-309 | | |
| CF | GULICK (2003) "New Antiviral Drugs," <i>Critical Microbiology and Infectious Diseases</i> 9:186-193 | | |
| CG | Hoggard et al. (2002) "Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules." <i>Current Opinion in Infectious Diseases</i> 15(1):3-8 | | |
| CH | Kiso et al. (1999) "Design of small peptidomimetic HIV-1 Protease Inhibitors and Prodrug Forms." 6(5):275-281 | | |
| CI | Krise et al. (1996) "Prodrugs of Phosphates, Phosphates, and Phosphinates." <i>Advanced Drug Delivery Reviews</i> 19(2):287-310 | | |
| CJ | Kubota et al. (1998) "Novel inhibitory effects of gamma-glutamylcysteine ethyl ester against human immunodeficiency virus type 1 production and propagation." <i>Antimicrobial Agents and Chemotherapy</i> 42(5):1200-1206 | | |
| CK | Lee et al. (2002) "In Vivo and In Vitro Characterization of GS 7340, an isopropylalaninyl phenyl ester prodrug of tenofovir: selective intracellular activation of GS 7340 leads to preferential distribution in lymphatic tissues. 9th Conference of Retroviruses and Opportunistic infections, Abstract No: 3847 | | |
| CL | Robbins et al. (1998) "Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of A Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphomethoxypropyl) Adenine (PMPA), Bis(isopropyloxymethylcarbonyl) PMPA" <i>Antimicrobial Agents and Chemotherapy</i> 42(3):612-617 | | |
| CL | Zimra et al. (2000) "Uptake of pivaloxymethyl butyrate into leukemic esterase-catalyzed hydrolysis." <i>Journal of Cancer Research and Clinical Oncology</i> 126(12):693-698 | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² CITE NO.: Those documents which are marked with an double asterisk (*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.